Glenmede Trust Co. NA held its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,900 shares of the medical instruments supplier’s stock at the end of the first quarter. Glenmede Trust Co. NA’s holdings in West Pharmaceutical Services were worth $330,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new position in shares of West Pharmaceutical Services during the fourth quarter valued at approximately $308,000. Kayne Anderson Rudnick Investment Management LLC increased its position in shares of West Pharmaceutical Services by 18.3% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 30,960 shares of the medical instruments supplier’s stock valued at $2,526,000 after buying an additional 4,787 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of West Pharmaceutical Services by 3.5% in the first quarter. Bank of New York Mellon Corp now owns 842,316 shares of the medical instruments supplier’s stock valued at $68,742,000 after buying an additional 28,302 shares in the last quarter. Karp Capital Management Corp acquired a new position in shares of West Pharmaceutical Services during the first quarter valued at approximately $2,497,000. Finally, SG Americas Securities LLC increased its position in shares of West Pharmaceutical Services by 414.0% in the first quarter. SG Americas Securities LLC now owns 17,089 shares of the medical instruments supplier’s stock valued at $1,395,000 after buying an additional 13,764 shares in the last quarter. 91.35% of the stock is currently owned by institutional investors and hedge funds.
Shares of West Pharmaceutical Services, Inc. (WST) traded down 0.40% on Tuesday, reaching $86.71. The company’s stock had a trading volume of 347,160 shares. West Pharmaceutical Services, Inc. has a 1-year low of $70.17 and a 1-year high of $99.91. The company’s 50 day moving average is $93.44 and its 200-day moving average is $88.71. The firm has a market cap of $6.42 billion, a price-to-earnings ratio of 37.21 and a beta of 1.10.
West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.01. The firm had revenue of $397.60 million for the quarter, compared to analyst estimates of $406 million. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.59 earnings per share. Equities research analysts expect that West Pharmaceutical Services, Inc. will post $2.70 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Wednesday, October 18th will be paid a $0.14 dividend. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.13. The ex-dividend date is Tuesday, October 17th. This represents a $0.56 annualized dividend and a yield of 0.65%. West Pharmaceutical Services’s dividend payout ratio is currently 22.22%.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/glenmede-trust-co-na-continues-to-hold-position-in-west-pharmaceutical-services-inc-wst-updated-updated-updated/1195459.html.
WST has been the topic of several recent analyst reports. Jefferies Group LLC reaffirmed a “hold” rating and issued a $90.00 price target (up from $82.00) on shares of West Pharmaceutical Services in a research report on Friday, April 28th. BidaskClub downgraded West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Finally, Zacks Investment Research raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Saturday, April 29th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $90.18.
In other West Pharmaceutical Services news, CFO William J. Federici sold 54,996 shares of the company’s stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $95.45, for a total value of $5,249,368.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.90% of the stock is owned by corporate insiders.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with our FREE daily email newsletter.